Welcome to our dedicated page for Channel Therapeutics Corporation news (Ticker: CHRO), a resource for investors and traders seeking the latest updates and insights on Channel Therapeutics Corporation stock.
Channel Therapeutics Corporation (CHRO) is a clinical-stage biotech pioneer developing non-opioid pain therapies by targeting the NaV1.7 sodium channel. This page provides investors and industry professionals with timely updates on the company’s clinical trials, research breakthroughs, and strategic initiatives.
Access the latest press releases, financial reports, and regulatory milestones in one centralized location. Track progress across key programs like CC8464 (neuropathic pain) and CT2000 (ocular pain), along with partnership announcements and scientific publications.
Our curated news collection ensures you stay informed on CHRO’s advancements in non-addictive pain management without promotional bias. Bookmark this page for efficient monitoring of clinical developments, FDA updates, and market positioning in the biotech sector.
Channel Therapeutics (NYSE: CHRO) has provided insights on the differences between NaV1.7 and NaV1.8 pain signal inhibitors, following Vertex Pharmaceutical's Phase 2 data announcement for Suzetrigine. The company emphasizes that while both are voltage-gated sodium channels in sensory neurons, NaV1.7 overexpression leads to more severe pain compared to NaV1.8's moderate pain effects.
Channel is pursuing a three-pronged approach with their NaV1.7 inhibitor: an oral treatment for neuropathic pain, an eye drop formulation for eye pain, and a slow-release depot formulation for post-surgical nerve blocks. The company expects critical data readouts in 2025 to validate their clinical development strategy.
Channel Therapeutics (NYSE: CHRO) announced positive results from preclinical trials of its NaV1.7 inhibitor nerve block formulations for acute pain. The study demonstrated superior efficacy and duration compared to bupivacaine, the current standard of care. Three out of four formulations showed better efficacy than bupivacaine, with one formulation remaining effective for over four days.
The trials included thermal hyperalgesia and mechanical allodynia tests in rodents, with multiple test arms including placebo, bupivacaine, and four Company formulations. Unlike current nerve block therapies that cause temporary paralysis, the NaV1.7 approach doesn't impact mobility, potentially offering better post-surgical physical therapy options.
The Company is targeting the post-operative global pain market, valued at $2.6 billion in 2023. Results for additional studies on eye drops for various types of eye pain are expected in late January 2025.
Channel Therapeutics (NYSE American: CHRO), formerly Chromocell, announced its name change and reincorporation in Nevada. The company focuses on developing non-opioid pain treatments through sodium channel modulation, specifically targeting NaV1.7. The company provided updates on three therapeutic programs: Depot Program for postoperative nerve blocks showing 96-hour sustained release in animals with pending efficacy results; Eye Pain Program with well-tolerated animal studies and expected Phase II human trials in Q2 2025; and a Chronic Pain program planned for Q1 2025 pending program-specific financing.
Chromocell Therapeutics (NYSE American: CHRO) has unveiled an injectable depot program using peripheral nerve blocks for post-operative pain treatment. The program leverages the company's NaV1.7 molecule, targeting a market of approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the US. The company's drug has shown no addictive properties in four Phase I trials and demonstrated strong efficacy in preclinical models. The program aims to reduce opioid usage and could benefit from NOPAIN Act provisions upon FDA approval.
Chromocell Therapeutics (NYSE American: CHRO), a non-opioid pain treatment developer, has announced its participation in two upcoming investor conferences. CEO Frank Knuettel II will present at the LDMicro Main Event XVII on October 29, 2024, from 10:00-10:25 AM PT in Los Angeles, and at the Spartan Capital Investor Conference on November 4, 2024, from 9:45-10:00 AM ET in NYC.
Both events offer opportunities for one-on-one meetings and networking with institutional investors, industry leaders, and capital market representatives. The LDMicro event focuses on showcasing emerging micro-cap companies, while the Spartan conference brings together public company executives and institutional investors for strategic discussions.
Chromocell Therapeutics (NYSE American: CHRO) has announced an amendment to its stock repurchase plan, increasing the total value of shares available for repurchase by an additional $500,000 to $750,000. The amendment also extends the plan's termination date from December 31, 2024, to June 30, 2025. The company's CEO Frank Knuettel stated this decision reflects their belief that the common stock is undervalued and represents an attractive investment at current prices. The repurchases may be conducted through open market or private transactions, subject to Rule 10b-18 regulations and trading plans under Rule 10b5-1.
Chromocell Therapeutics (NYSE American: CHRO), a leader in non-opioid pain treatment development, will present at the H.C. Wainwright 26th Annual Global Investment Conference. CEO Frank Knuettel will provide a company overview, with the virtual presentation available from September 9th at 7:00 A.M. (ET).
Institutional investors can register at www.hcwevents.com/annualconference. The presentation will be accessible through Chromocell's Investor section website, with an archived replay available for at least 30 days. This event allows Chromocell to highlight its progress in developing innovative non-opioid pain treatments, focusing on modulating NaV1.7 receptors in the peripheral nervous system.
Chromocell Therapeutics (NYSE American: CHRO), a pioneer in non-opioid pain treatment development, has announced a stock repurchase plan of up to $250,000 of its common stock. This represents approximately 23% of the non-affiliate float based on the August 6, 2024 closing price. The plan, which is discretionary and can be modified or terminated at any time, aims to enhance stockholder value.
CEO Frank Knuettel stated that while the company remains focused on allocating capital to clinical and pre-clinical programs, they believe the current stock price doesn't reflect their progress in developing drugs for neuropathic and chronic pain. The company views its stock as an attractive investment opportunity and expects to make announcements in the coming months supporting their drug development efforts.
Chromocell Therapeutics (NYSE American: CHRO), a leader in non-opioid pain treatment development, has announced its participation in the Virtual Investor Lunch Break Series. The event, titled 'The Chromocell Opportunity,' is scheduled for Thursday, July 18, 2024, at 12:00 PM ET.
Frank Knuettel II, serving as both CEO and CFO, will present a corporate overview and business outlook. The session will include a live Q&A segment, allowing attendees to submit questions. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Chromocell Therapeutics , listed as CHRO on NYSE American, will have its CEO present at Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The conference will feature top healthcare companies discussing industry catalysts and future trends. Investors can attend the 20-minute 'fireside chat' style presentations online.
